Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses
Open Access
- 15 June 2021
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-15
Abstract
PPM1D/Wip1 is a negative regulator of the tumor suppressor p53 and is overexpressed in several human solid tumors. Recent reports associate gain-of-function mutations of PPM1D in immune cells with worse outcomes for several human cancers. Here we show that mice with genetic knockout of Ppm1d or with conditional knockout of Ppm1d in the hematopoietic system, in myeloid cells, or in neutrophils all display significantly reduced growth of syngeneic melanoma or lung carcinoma tumors. Ppm1d knockout neutrophils infiltrate tumors extensively. Chemical inhibition of Wip1 in human or mouse neutrophils increases anti-tumor phenotypes, p53-dependent expression of co-stimulatory ligands, and proliferation of co-cultured cytotoxic T cells. These results suggest that inhibition of Wip1 in neutrophils enhances immune anti-tumor responses.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U01HG004085, U01HG004080)
- U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
- Russian Foundation for Basic Research (19-315-51035)
- Russian Science Foundation (19-75-20128)
- Fondation ARC pour la Recherche sur le Cancer
- Ligue Contre le Cancer
This publication has 94 references indexed in Scilit:
- Mouse large-scale phenotyping initiatives: overview of the European Mouse Disease Clinic (EUMODIC) and of the Wellcome Trust Sanger Institute Mouse Genetics ProjectMammalian Genome, 2012
- Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agentsProceedings of the National Academy of Sciences, 2011
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsJournal of Experimental Medicine, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsJournal of Experimental Medicine, 2011
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- The role of TNF superfamily members in T-cell function and diseasesNature Reviews Immunology, 2009
- The capacity of the TNF family members 4‐1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cellsEuropean Journal of Immunology, 2008
- Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formationNature, 2008
- Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1DJournal of Neuro-Oncology, 2007
- Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphataseJournal of Experimental Medicine, 2006